186 related articles for article (PubMed ID: 22030032)
1. Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases.
Miles TJ; Barfoot C; Brooks G; Brown P; Chen D; Dabbs S; Davies DT; Downie DL; Eyrisch S; Giordano I; Gwynn MN; Hennessy A; Hoover J; Huang J; Jones G; Markwell R; Rittenhouse S; Xiang H; Pearson N
Bioorg Med Chem Lett; 2011 Dec; 21(24):7483-8. PubMed ID: 22030032
[TBL] [Abstract][Full Text] [Related]
2. Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases.
Miles TJ; Axten JM; Barfoot C; Brooks G; Brown P; Chen D; Dabbs S; Davies DT; Downie DL; Eyrisch S; Gallagher T; Giordano I; Gwynn MN; Hennessy A; Hoover J; Huang J; Jones G; Markwell R; Miller WH; Minthorn EA; Rittenhouse S; Seefeld M; Pearson N
Bioorg Med Chem Lett; 2011 Dec; 21(24):7489-95. PubMed ID: 22047689
[TBL] [Abstract][Full Text] [Related]
3. Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases.
Miles TJ; Hennessy AJ; Bax B; Brooks G; Brown BS; Brown P; Cailleau N; Chen D; Dabbs S; Davies DT; Esken JM; Giordano I; Hoover JL; Jones GE; Kusalakumari Sukmar SK; Markwell RE; Minthorn EA; Rittenhouse S; Gwynn MN; Pearson ND
Bioorg Med Chem Lett; 2016 May; 26(10):2464-2469. PubMed ID: 27055939
[TBL] [Abstract][Full Text] [Related]
4. Discovery and structure-activity relationships of a novel isothiazolone class of bacterial type II topoisomerase inhibitors.
Cooper IR; McCarroll AJ; McGarry D; Kirkham J; Pichowicz M; Walker R; Warrilow C; Salisbury AM; Savage VJ; Moyo E; Forward H; Cheung J; Metzger R; Gault Z; Nelson G; Hughes D; Cao S; Maclean J; Charrier C; Craighead M; Best S; Stokes NR; Ratcliffe AJ
Bioorg Med Chem Lett; 2016 Sep; 26(17):4179-83. PubMed ID: 27499455
[TBL] [Abstract][Full Text] [Related]
5. Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases.
Miles TJ; Hennessy AJ; Bax B; Brooks G; Brown BS; Brown P; Cailleau N; Chen D; Dabbs S; Davies DT; Esken JM; Giordano I; Hoover JL; Huang J; Jones GE; Sukmar SK; Spitzfaden C; Markwell RE; Minthorn EA; Rittenhouse S; Gwynn MN; Pearson ND
Bioorg Med Chem Lett; 2013 Oct; 23(19):5437-41. PubMed ID: 23968823
[TBL] [Abstract][Full Text] [Related]
6. Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2).
Singh SB; Kaelin DE; Wu J; Miesel L; Tan CM; Black T; Nargund R; Meinke PT; Olsen DB; Lagrutta A; Lu J; Patel S; Rickert KW; Smith RF; Soisson S; Sherer E; Joyce LA; Wei C; Peng X; Wang X; Fukuda H; Kishii R; Takei M; Takano H; Shibasaki M; Yajima M; Nishimura A; Shibata T; Fukuda Y
Bioorg Med Chem Lett; 2015 May; 25(9):1831-5. PubMed ID: 25851938
[TBL] [Abstract][Full Text] [Related]
7. In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases.
Charrier C; Salisbury AM; Savage VJ; Moyo E; Forward H; Ooi N; Cheung J; Metzger R; McGarry D; Walker R; Cooper IR; Ratcliffe AJ; Stokes NR
J Antimicrob Chemother; 2016 Oct; 71(10):2831-9. PubMed ID: 27353465
[TBL] [Abstract][Full Text] [Related]
8. Conformational constraint in oxazolidinone antibacterials. Part 2: Synthesis and structure-activity studies of oxa-, aza-, and thiabicyclo[3.1.0]hexylphenyl oxazolidinones.
Renslo AR; Gao H; Jaishankar P; Venkatachalam R; Gómez M; Blais J; Huband M; Vara Prasad JV; Gordeev MF
Bioorg Med Chem Lett; 2006 Mar; 16(5):1126-9. PubMed ID: 16387498
[TBL] [Abstract][Full Text] [Related]
9. Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099).
Basarab GS; Hill PJ; Garner CE; Hull K; Green O; Sherer BA; Dangel PB; Manchester JI; Bist S; Hauck S; Zhou F; Uria-Nickelsen M; Illingworth R; Alm R; Rooney M; Eakin AE
J Med Chem; 2014 Jul; 57(14):6060-82. PubMed ID: 24959892
[TBL] [Abstract][Full Text] [Related]
10. Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
Basarab GS; Manchester JI; Bist S; Boriack-Sjodin PA; Dangel B; Illingworth R; Sherer BA; Sriram S; Uria-Nickelsen M; Eakin AE
J Med Chem; 2013 Nov; 56(21):8712-35. PubMed ID: 24098982
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and structure-activity relationships of benzophenone-based tetraamides as novel antibacterial agents.
Vooturi SK; Cheung CM; Rybak MJ; Firestine SM
J Med Chem; 2009 Aug; 52(16):5020-31. PubMed ID: 19653650
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antibacterial activity of the C-7 side chain of 3-aminoquinazolinediones.
Hutchings KM; Tran TP; Ellsworth EL; Watson BM; Sanchez JP; Showalter HD; Stier MA; Shapiro M; Themis Joannides E; Huband M; Nguyen DQ; Maiti S; Li T; Tailor J; Thomas G; Ha C; Singh R
Bioorg Med Chem Lett; 2008 Sep; 18(18):5087-90. PubMed ID: 18752951
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
Li Q; Chu DT; Claiborne A; Cooper CS; Lee CM; Raye K; Berst KB; Donner P; Wang W; Hasvold L; Fung A; Ma Z; Tufano M; Flamm R; Shen LL; Baranowski J; Nilius A; Alder J; Meulbroek J; Marsh K; Crowell D; Hui Y; Seif L; Melcher LM; Plattner JJ
J Med Chem; 1996 Aug; 39(16):3070-88. PubMed ID: 8759628
[TBL] [Abstract][Full Text] [Related]
14. Isothiazolopyridones: synthesis, structure, and biological activity of a new class of antibacterial agents.
Wiles JA; Hashimoto A; Thanassi JA; Cheng J; Incarvito CD; Deshpande M; Pucci MJ; Bradbury BJ
J Med Chem; 2006 Jan; 49(1):39-42. PubMed ID: 16392790
[TBL] [Abstract][Full Text] [Related]
15. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents.
Mitscher LA
Chem Rev; 2005 Feb; 105(2):559-92. PubMed ID: 15700957
[No Abstract] [Full Text] [Related]
16. Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis.
Gomez L; Hack MD; Wu J; Wiener JJ; Venkatesan H; Santillán A; Pippel DJ; Mani N; Morrow BJ; Motley ST; Shaw KJ; Wolin R; Grice CA; Jones TK
Bioorg Med Chem Lett; 2007 May; 17(10):2723-7. PubMed ID: 17368897
[TBL] [Abstract][Full Text] [Related]
17. Determination of the primary molecular target of 1,2,4-triazole-ciprofloxacin hybrids.
Plech T; Kaproń B; Paneth A; Kosikowska U; Malm A; Strzelczyk A; Stączek P; Świątek Ł; Rajtar B; Polz-Dacewicz M
Molecules; 2015 Apr; 20(4):6254-72. PubMed ID: 25859782
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in vitro activity of a series 1beta-methylcarbapenem derivatives.
Jeon HC; Kim JW; Hong JH; Cho JH; Oh CH
Eur J Med Chem; 2006 Oct; 41(10):1201-9. PubMed ID: 16797791
[TBL] [Abstract][Full Text] [Related]
19. Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
Hossion AM; Zamami Y; Kandahary RK; Tsuchiya T; Ogawa W; Iwado A; Sasaki K
J Med Chem; 2011 Jun; 54(11):3686-703. PubMed ID: 21534606
[TBL] [Abstract][Full Text] [Related]
20. Novel inhibitors of bacterial protein synthesis: structure-activity relationships for 1,8-naphthyridine derivatives incorporating position 3 and 4 variants.
Clark RF; Wang S; Ma Z; Weitzberg M; Motter C; Tufano M; Wagner R; Gu YG; Dandliker PJ; Lerner CG; Chovan LE; Cai Y; Black-Schaefer CL; Lynch L; Kalvin D; Nilius AM; Pratt SD; Soni N; Zhang T; Zhang X; Beutel BA
Bioorg Med Chem Lett; 2004 Jun; 14(12):3299-302. PubMed ID: 15149694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
